In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative as a follow-up and evolutive next step to the former New Drugs for Bad Bugs programme. European Biotechnology spoke with Rob Stavenger, its coordinator at GlaxoSmithKline, about the goals of the €295m initiative, its cooperation with SMEs, and the relevance of push and pull incentives in the field.
Recipharm founder to lead Amarna board
AppointmentsAmarna Therapeutics has appointed a new Supervisory Board, led by healthcare and biotech pioneer Thomas Eldered.
Researchers identify viral inflammation switch
Latest NewsA team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
EIT Innovator Award: Marc Julien awarded
AppointmentsDiabeloop CEO Marc Julien has won the EIT Innovators Award.
Rotavirus vaccines kill cancer cells
Latest NewsResearchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Polyphor presents AMR breaker
Latest NewsSwiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
IMI AMR Accelerator: Allow the few to make the most of their resources
OpinionIn 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative as a follow-up and evolutive next step to the former New Drugs for Bad Bugs programme. European Biotechnology spoke with Rob Stavenger, its coordinator at GlaxoSmithKline, about the goals of the €295m initiative, its cooperation with SMEs, and the relevance of push and pull incentives in the field.
The AMR business (Part II)
BackgroundSMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Zealand Pharma acquires Encycle
Latest NewsZealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
The AMR business (Part I)
BackgroundAntibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.
Researchers target ferroptosis resistance of cancer cells
Latest NewsGerman researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.